Skip to main content

Main menu

  • About Us
    • Leadership
    • Our Team
    • Vision, Mission and Values
    • Health and Economic Impact
    • Strategic Plan
  • Our Research
    • Research Focus
      • Brain Health
      • Cancer
      • Cardiovascular Conditions and Diseases
      • Digital Health
      • Health Policy
      • Immunity and Infectious Diseases
      • Joint Health and Mobility
      • Respiratory and Lung Health
      • Spinal Cord Injury and Rehabilitation
    • Research Centres and Programs
      • BC Centre on Substance Use
      • Centre for Cardiovascular Innovation
      • Centre for Clinical Epidemiology and Evaluation
      • Centre for Hip Health and Mobility
      • Centre for Lung Health
      • Djavad Mowafaghian Centre for Brain Health
      • Immunity and Infection Research Centre
      • International Collaboration On Repair Discoveries
      • Ovarian Cancer Research Centre
      • Vancouver Prostate Centre
      • Community Research Program
      • Emergency Medicine Research Program
      • Hematology Research Program
      • Rehabilitation Research Program
      • Skin Research Program
      • Other Research Focus Areas
    • News and Stories
    • Researcher Directory
    • Events and Workshops
  • Research Services
    • New to VCHRI
      • Working at VCHRI
      • Regulations and Training
      • Membership with VCHRI
    • Starting Your Project
      • Research Facilitation
      • Awards and Funding
      • Grant Management
      • Operational Approval
    • Developing Your Project
      • Clinical Trials Administration
      • Clinical Research Unit
      • CST Cerner at VCH
      • Research Privacy
      • Financial Policies and Procedures
    • Additional Support
      • Education and Training
      • Communications and Branding
      • Media Relations
      • Study Recruitment Support
      • Innovation and Industry Partnership
    • Internal Awards
    • Clinical Research
    • Innovation and Partnership
  • Participate in Research
    • Reasons to Participate
    • Participant Stories
    • Find a Study
    • Recruitment Support

User menu

  • Log in

Breadcrumb

  1. Home
  2. Our Research
  3. News and Stories
  4. A nano silver bullet for treatment-resistant bacteria

A nano silver bullet for treatment-resistant bacteria

Stories Feb 20, 2022 3 minutes

Researchers have discovered a way to destroy mycobacteria superbugs using a nano-sized approach.

Antimicrobial resistance is one of the top 10 global health threats, according to the World Health Organization. Taking the form of bacteria and fungi unresponsive to antibiotics and other treatments, these superbugs affect one in 16 Canadians admitted to hospital.

One such infection is caused by members of the mycobacteria family: a prevalent, treatment-resistant bacteria whose irregularly shaped microscopic rods spread through airborne particles of infected soil, fluids or dust. Mycobacteria targets macrophages in the body, specialist cells that form part of the immune system and are designed to detect and destroy pathogens, such as bacteria. 

A new research study led by Vancouver Coastal Health Research Institute researcher Dr. Horacio Bach has identified a novel approach to destroying antibiotic-resistant nontuberculous mycobacteria. 

“This is the first paper to show that you can kill multiplying intracellular Mycobacterium using an antibacterial agent instead of antibiotics.” 

Bach and his research team encapsulated antibacterial agents and lignin-silver nanoparticles inside vesicles termed niosomes. This helps to internalize the nanoparticles inside macrophages. Upon binding to the cell membrane of macrophages, the niosome delivers its nanoparticle payload into the infected macrophages with detrimental consequences to the intracellular mycobacteria.

Published in the journal Nanomaterials, Bach’s study paves the way for new treatments for conditions that are particularly susceptible to Mycobacterium abscessus, a type of nontuberculous mycobacterial infection.

Lignin-capped silver nanoparticle nanoniosomes depicted at a magnification of 20 nanometres.

At 126.1 nanometres in size — 80,000 to 100,000 times smaller than the thickness of a human hair — the nanoniosomes Bach and his team developed were also significantly smaller than those used in other studies that investigated niosome treatments for mycobacterial infection. These typically ranged between 4.2 and 8.7 micrometres — around 70 times smaller than the diameter of a human hair. 

Mycobacteria are around 0.3-0.5 micrometres, making Bach’s nanoniosomes a fraction of the size of their target.

A personalized approach could help overcome antimicrobial resistance

Responsible for tuberculosis and leprosy, along with other conditions involving the infection of macrophages, the waxy and complex cell walls of mycobacteria protect them or delay the penetration of antibiotics, such as isoniazid. Some strains can be treated with the antibiotics clarithromycin and rifamycin, but many treatment-resistant strains evade even these. 

“Our arsenal of effective antibiotics is shrinking, which is why we need to find new treatment approaches to overcome this barrier.”

People with cystic fibrosis — a genetic condition that damages the lungs and other organs — along with the lung-capacity-reducing chronic obstructive pulmonary disease are more vulnerable to a severe mycobacterial infection.

“Cystic fibrosis patients cannot clear fluids from their lungs properly. This makes their lungs prone to infections and more likely to contract a strain of potentially fatal treatment-resistant mycobacterial,” says Bach.

Dr. Horacio Bach is a researcher with the Immunity and Infection Research Centre and a clinical assistant professor in the Faculty of Medicine, Division of Infectious Diseases at the University of British Columbia.

While more research is needed to investigate the breadth of possibilities of Bach’s discovery, he believes these results are a positive indication of the future applications of the nanoniosomes he and his team have developed.
 
“This has the potential to become a targeted therapy for people with conditions such as cystic fibrosis, along with tuberculosis and other conditions that involve infection of the macrophages.”

 

Researchers

Horacio Bach

Related Articles

Antibiotics taken during labour and delivery not linked to autism

Antibiotic for preventing surgical infections proven safe in penicillin-allergic patients

New evidence calls into question vitamin C as a treatment for sepsis

Share:

  • Facebook
  • Linkedin
  • Twitter
  • Email

Related Research Centres/Programs

Immunity and Infection Research Centre

Get the latest research headlines in your inbox

Subscribe

Recent News and Stories

Type
Participate in Research

Reaching for the stars: Virtual reality program creates new experiences for seniors in long-term care

Feb 3, 2023 participate, technology, mental health
Type
Announcement

VCHRI researchers awarded CIHR project grants to support health research

Feb 2, 2023
Type
Stories

Eye movements could be a window into brain health and function

Feb 1, 2023 brain, parkinsons, mobility
See more news

Get updates!

Join our newsletter mailing list to stay up to date on features and releases.

Subscribe

Quick Links

  • News and Stories
  • Careers
  • Events
  • Media Enquiries

Follow Us

  • Twitter
  • LinkedIn

© 2023 VCHRI. All rights reserved.

  • Contact
  • Privacy Policy